SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Robloxs quarterly results beat some estimates, but the weaker user metrics and outlook for a year-over-year decline in fourth-quarter bookings sparked a sharp selloff. Traders are largely focused on slowing engagement and monetization, while some see the drop as a buying opportunity.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is under pressure as falling lithium spot and futures prices weigh on sentiment ahead of earnings, with traders questioning where prices and the stock will bottom. Some see the selloff as an opportunity given longer-term battery and storage demand, while others expect further downside and want clearer guidance on lithium-price recovery.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas announced addition to the S&P 500 is drawing attention, with traders expecting index-fund buying but debating whether the inclusion could be followed by a sell-the-news pullback. The discussion also reflects caution after a strong run, with bears pointing to valuation and modest growth despite recent earnings beats.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to fresh 52-week highs is drawing attention ahead of its expected earnings report, with traders also speculating about a possible buyout and short covering. The acquisition talk is unconfirmed; some traders instead point to BRIUMVIs growth and earnings expectations as support for the rally.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Updated Phase 3 VIKTORIA-1 subgroup data in PIK3CA-mutant breast cancer is driving discussion, with traders highlighting the gedatolisib regimens efficacy versus the comparator. The positive clinical reaction is tempered by debate over the pending FDA label expansion and whether Celcuity can translate its approved drug into meaningful commercial uptake.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSparks steep selloff is drawing attention as bitcoin miners and AI/data-center infrastructure stocks face broad pressure, with traders citing macroeconomic concerns, financing costs and leverage despite Bitcoin strength. The debate centers on whether the Meta data-center lease and bitcoin holdings support a buy-the-dip case or whether debt, sector weakness and management concerns will keep weighing on shares.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Brazils election outcome has sparked a broad selloff in Brazilian-linked stocks, with traders concerned about political and economic risk weighing on Nus Brazil-heavy business. Many investors argue the reaction is an overreaction because the companys fundamentals remain intact, while others expect continued volatility.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubos steep, low-volume selloff and repeated lows dominate discussion, with traders looking ahead to earnings and CEO Alisa Bowens strategic update for evidence of a turnaround. Bulls point to potential Disney integration and improved profitability, while bears question the business outlook and expect further weakness; no catalyst is clearly confirmed as driving the decline.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is caught in a broader tech and semiconductor selloff as investors question whether heavy AI infrastructure spending will generate adequate returns, with weak Intel guidance and Amazons spending outlook adding to the pressure. Traders are divided between viewing the pullback as an AI-bubble warning and treating it as a buying opportunity, citing continued chip demand and Nvidias business strength.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts strong quarterly results and accelerating Azure growth drew attention, but the post-earnings rally faded as traders weighed its planned bond sale and heavy AI infrastructure spending amid a broader tech selloff. The community is split between seeing Azure demand and cash generation as evidence the investments are paying off and worrying that rising funding needs could pressure returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases

Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases...

Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?

Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why

Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial 

Equity

Data from a higher dose population is now expected in the second half of 2026.

Cabaletta Bio (NASDAQ:CABA) Receives "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued an 'overweight' rating and issued a $30.00 price target on shares of Cabaletta Bio in a research report on Monday...

Stock Traders Buy High Volume of Call Options on Cabaletta Bio (NASDAQ:CABA)

Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) saw unusually large options trading on Wednesday. Stock investors acquired 11,001 call options on the stock. This is an increase of 756% compared...

Wall Street Zen Downgrades Cabaletta Bio (NASDAQ:CABA) to Sell

Wall Street Zen downgraded shares of Cabaletta Bio from a "hold" rating to a "sell" rating in a report on Saturday...

First Patients Dosed with Cabaletta Bios Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.s (Cabaletta Bio or Cabaletta) (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has been infused into the first two patients using drug...

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Moderate Buy" by Analysts

Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One...

Cabaletta Bio, Inc. $CABA Position Raised by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 565.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional...

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Cabaletta Bio Inc

Bullish Sentiment

<ul class="summary-bullets"><li>The company was studying its therapy called rese-cel at the lowest dose without preconditioning in patients with pemphigus vulgaris.</li><li>After discontinuing all immunomodulators, two of the four patients demonstrated compelling clinical activity through 6 months of follow-up.</li><li>While a mild immune reaction was observed in one of the patients, no neurological complications were observed, the company said.</li></ul>Shares of Cabaletta Bio Inc (CABA) jumped 30% on Monday, on track for its best day since October, after the company reported promising early data from four patients with an autoimmune disease treated with the company’s experimental cell therapy, demonstrating clinical activity without any preconditioning chemotherapy.The company said that four patients with pemphigus vulgaris, an autoimmune disease causing severe blistering of the skin, received its therapy called rese-cel at the lowest dose without preconditioning with cyclophosphamide and fludarabine. After discontinuing all immunomodulators, two of the four patients demonstrated compelling clinical activity through 6 months of follow-up, while three patients remained off all immunomodulators and steroids, the company said. &nbsp;While a mild immune reaction was observed in one of the patients, no neurological complications were observed, the company said. &nbsp;The company also said that it has enrolled patients to test a higher dose of its therapy based on the safety profile observed in the lower dose cohort.Data from the higher dose population is now expected in the second half of 2026.<h2 class="st-heading-2">CABA’s $150M Financing</h2>Separately, Cabaletta Bio priced an underwritten offering of 51.73 million shares of common stock at $2.90 per share, expected to generate gross proceeds of approximately $150 million before underwriting discounts, commissions, and expenses. &nbsp;The financing drew participation from big-pharma company Eli Lilly and Company, in addition to existing investors including Bain Capital Life Sciences, Adage Capital Management, and Cormorant Asset Management.<h2 class="st-heading-2">How Did CABA Retail Traders React?</h2>On Stocktwits, retail sentiment around CABA stock rose from 'neutral' to 'bullish' territory over the past 24 hours, while message volume increased from 'normal' to 'high' levels.A Stocktwits user opined that the company's shares are cheap at current prices.<stembedurl>https://www.stocktwits.com/Bronco6970/message/652199318</stembedurl>Another voiced optimism about Eli Lilly’s participation in the financing round, opining that it could lead to a “full collaboration or acquisition later.”<stembedurl>https://www.stocktwits.com/Bronco6970/message/652191768</stembedurl>A third user opined that there is potential for making “mega money” on the stock.<stembedurl>https://www.stocktwits.com/10xorbust/message/652194633</stembedurl><a href="https://stocktwits.com/symbol/CABA">CABA stock</a> has gained 200% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-crcl-stock-rallying-calrity/cZQMUhfReJ1">Circle Stock Extends Gains, Hits 1-Month High On CLARITY Act Momentum</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cabaletta Bio logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Lilly(Eli) & Co

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.51
Prev Close	$1.59
Open	$1.55
Dividend Yield	0.00%
50-Day Moving Average	$2.30
Beta	1.80
Avg. Volume	6.32M
PE Ratio	-0.95

52-Week High	$4.23
52-Week Low	$1.32
Market Capitalization	$268.73M
EPS (Annual)	-$2.10
Price to Book	1.20
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CABA Fundamentals